Azitra, Inc. Announces Q3 2026 Results and Provides Business Updates
Anitra Q3 EPS $(0.29) Misses $(0.23) Estimate
Azitra, Inc. to Present Research at BIO-Europe® Showing ATR-COSF Reduced Fine Lines and Improved Elasticity in Ex Vivo Human Skin Models
Azitra To Present Pipeline Updates Including Results For ATR-COSF Program, Designed To Deliver Filaggrin Domains Into Human Skin To Reduce Appearance Of Fine Lines And Wrinkles, At BIO-Europe
AZTR: Update on Rash, Fine Lines & Elasticity
Azitra, Inc. Expands Eligibility for ATR-04 Phase 1/2 Clinical Trial to Include Patients with Rashes due to KRAS and MEK Inhibitors
Azitra Expands Eligibility For Ongoing Phase 1/2 Clinical Trial Of ATR04-484 To Include Individuals With Rash Associated With KRAS And MEK Inhibitors
Azitra, Inc. Announces Revitalizing Results from Ex Vivo Study of ATR-COSF Demonstrating Ability to Reduce Fine Lines and Improve Elasticity in Human Skin
Azitra Suspends ATM Offering Program For The Foreseeable Future; From September 28, 2026 - October 26, 2026, The Company Sold An Aggregate Of 1,000 Shares Of Common Stock Under The ATM Program For Aggregate Gross Proceeds Of ~$126
Azitra To Present Progress For Its Cosmetic ATR-COSF Program Targeting Fine Lines And Wrinkles At Bio-europe, November 10; First-In-Human Study With ATR-COSF Initial Results Anticipated By End Of 2026
Azitra, Inc. Announces Reverse Stock Split
Azitra Enters Sales Agreement With A.G.P. For Common Stock Offering; May Offer Common Stock Up To $3.50M Through A.G.P.
AZTR: Updated Valuation Reflects Cosmetic and EGFRi Rash Programs
Azitra, Inc. to Present at the H.C. Wainwright 28th Annual Global Investment Conference
Azitra, Inc. Regains Compliance with NYSE American Continued Listing Standards
Azitra Regains NYSE American Compliance
Azitra, Inc. Announces Q2 2026 Results and Provides Business Updates
Anitra Q2 EPS $(0.17) Misses $(0.12) Estimate
Azitra Reports Results From Two Ex Vivo Human Skin Tissue Studies Evaluating Distribution And Anti-Wrinkle Activity Of Filaggrin Domain Supernatant
/C O R R E C T I O N -- Azitra, Inc./
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.